Cyclacel Pharmaceuticals Inc (CYCC) — Financial Flexibility Index
Cyclacel Pharmaceuticals Inc (CYCC) has a Financial Flexibility Index of -1.37x as of June 2025. Free cash flow of $-1.06K (operating CF $-1.06K minus capex $0.00) represents -1% of total liabilities ($770.00). Check CYCC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cyclacel Pharmaceuticals Inc Financial Flexibility Index (2003–2024)
Historical Financial Flexibility Index trend for Cyclacel Pharmaceuticals Inc across 22 annual periods. See CYCC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Cyclacel Pharmaceuticals Inc (2003–2024)
Year-by-year free cash flow to debt coverage for Cyclacel Pharmaceuticals Inc. For the full company profile including market capitalisation, see Cyclacel Pharmaceuticals Inc (CYCC) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.27x | $-7.99 Million | $-7.99 Million | $6.27 Million | ▲ +35.1% |
| 2023 | -1.96x | $-16.11 Million | $-16.11 Million | $8.20 Million | ▲ +28.1% |
| 2022 | -2.73x | $-20.82 Million | $-20.83 Million | $7.62 Million | ▲ +19.6% |
| 2021 | -3.40x | $-18.51 Million | $-18.54 Million | $5.44 Million | ▼ -53.7% |
| 2020 | -2.21x | $-7.84 Million | $-7.93 Million | $3.54 Million | ▲ +15.3% |
| 2019 | -2.61x | $-9.44 Million | $-9.45 Million | $3.61 Million | ▼ -78.5% |
| 2018 | -1.46x | $-6.66 Million | $-6.70 Million | $4.55 Million | ▲ +16.9% |
| 2017 | -1.76x | $-7.47 Million | $-7.48 Million | $4.24 Million | ▲ +5.7% |
| 2016 | -1.87x | $-10.08 Million | $-10.08 Million | $5.39 Million | ▲ +23.2% |
| 2015 | -2.43x | $-14.43 Million | $-14.46 Million | $5.93 Million | ▼ -1.8% |
| 2014 | -2.39x | $-18.39 Million | $-18.70 Million | $7.70 Million | ▲ +0.4% |
| 2013 | -2.40x | $-17.99 Million | $-18.20 Million | $7.50 Million | ▼ -86.2% |
| 2012 | -1.29x | $-12.03 Million | $-12.04 Million | $9.34 Million | ▲ +40.1% |
| 2011 | -2.15x | $-13.97 Million | $-13.98 Million | $6.50 Million | ▲ +12.4% |
| 2010 | -2.45x | $-16.04 Million | $-16.04 Million | $6.54 Million | ▼ -58.8% |
| 2009 | -1.55x | $-15.18 Million | $-15.19 Million | $9.82 Million | ▲ +46.0% |
| 2008 | -2.86x | $-29.54 Million | $-29.91 Million | $10.31 Million | ▼ -140.5% |
| 2007 | -1.19x | $-21.37 Million | $-23.14 Million | $17.94 Million | ▲ +42.9% |
| 2006 | -2.08x | $-19.50 Million | $-20.17 Million | $9.36 Million | ▲ +30.8% |
| 2005 | -3.01x | $-20.61 Million | $-21.51 Million | $6.84 Million | ▼ -107.9% |
| 2004 | -1.45x | $-16.64 Million | $-21.09 Million | $11.48 Million | ▼ -733.3% |
| 2003 | -0.17x | $-14.49 Million | $-15.49 Million | $83.34 Million | — |